SMARCE1 and ovarian cancer: In contrast, SMARCE1 expression was not predictive of survival for patients diagnosed with later-stage ovarian cancer tumors (stages III and IV) (n = 1,268, HR = 1.093, P = 0.286) (Fig. 2 C, Bottom).